Rice Hall James & Associates LLC Reduces Position in Johnson & Johnson (NYSE:JNJ)

Rice Hall James & Associates LLC cut its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.1% in the third quarter, Holdings Channel.com reports. The firm owned 11,102 shares of the company’s stock after selling 360 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Johnson & Johnson were worth $1,814,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in JNJ. Morton Brown Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares during the period. Goodman Advisory Group LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth about $39,000. Cardinal Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the period. First Bank & Trust boosted its stake in shares of Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after purchasing an additional 156 shares during the period. Finally, Heritage Wealth Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $84,000. 67.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Barclays assumed coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Finally, Raymond James reduced their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $181.75.

Insider Buying and Selling

In related news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock worth $40,960,735 in the last 90 days. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.3 %

NYSE JNJ opened at $168.31 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm has a market cap of $440.04 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a 50 day moving average price of $176.07 and a 200 day moving average price of $171.13. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.